Less Ads, More Data, More Tools Register for FREE

Pin to quick picksZotefoams Plc Regulatory News (ZTF)

Share Price Information for Zotefoams Plc (ZTF)

Share Price is delayed by 15 minutes
Get Live Data
434.50    -0.50 (-0.11%)
Bid:
432.50
Ask:
435.00
Spread: 2.50 (0.578%)
Market Cap: £213.70m
ZTF Live PriceLast checked at - London Stock Exchange

Intraday Zotefoams Plc Share Chart

Trading Update

10 Jul 2015 07:00

RNS Number : 6817S
Zotefoams PLC
10 July 2015
 



Zotefoams plc

("Zotefoams" or "the Company")

 

Trading Update

 

 

10 July 2015 - Zotefoams, a world leader in cellular material technology, today provides a trading update for the six months ended 30 June 2015.

 

For the first six months of 2015 Zotefoams will deliver sales1 growth of approximately 8%, which is approximately 10% on a constant currency basis. Zotefoams expects revenue from MuCell Extrusion LLC, the Company's technology licensing business, to grow by around 40% and High-Performance Products ("HPP") sales growth to exceed 20%, building on the very strong HPP performance in 2014. The Company's Polyolefin foams sales volumes have increased by 6% and this is expected to deliver an increase in revenue of approximately 5%, equivalent to around 8% in constant currency. All three business units have strong forward order books.

 

The price of LDPE (Low Density Polyethylene), the Company's major raw material, was at a similar average euro price to the first half of 2014, although prices have risen sharply in recent months. The weaker euro has benefitted raw material purchases, which are significantly euro based, and US dollar sales have benefitted from the stronger dollar. However this has been more than offset by the impact of the euro on both Zotefoams' European sales and, in particular, the unhedged translational impact on the Company's balance sheet.

 

In Walton, Kentucky, USA, the major investment to increase global manufacturing capacity in support of future growth is proceeding to schedule.

 

Whilst being mindful of the potential impact of economic conditions the Company continues to expect 2015 to be another year of progress and remains confident about the long-term prospects for the business.

 

Zotefoams expects to announce its interim results for the six months ended 30 June 2015 on Tuesday 4 August 2015.

 

 

Enquiries:

Zotefoams plc

David Stirling, Group CEO

0208-664-1600

Clifford Hurst, Finance Director

FTI Consulting

0203-727-1000

Victoria Foster Mitchell/Simon Conway

 

 

Notes

 

1 Sales consolidates all external sales made by the joint-ventures as well as those made by Zotefoams plc and its subsidiaries.

2 Foreign exchange rates were:

 

H1:2015 average

H1:2014 average

30 Jun 2015

31 Dec 2014

Euro

1.378

1.223

1.412

1.289

USD

1.530

1.673

1.574

1.559

 

 

About Zotefoams plc

Zotefoams plc (LSE - ZTF) is a world leader in cellular material technology. Using a unique manufacturing process with environmentally friendly nitrogen expansion, Zotefoams produces lightweight foams in Croydon, UK and Kentucky, USA for diverse markets worldwide through its global sales force. Zotefoams also owns and licenses patented MuCell® microcellular foam technology from a base in Massachusetts, USA to customers worldwide and sells T-Tubes® advanced insulation systems made from its patented ZOTEK® fluoropolymer foams.

 

www.zotefoams.com

 

ZOTEK® is a registered trademark of Zotefoams plc. MuCell® is a registered trademark of Trexel Inc. T-Tubes® is a registered trademark of UFP Technologies Inc.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTFMGGNZLMGKZZ
Date   Source Headline
16th Jul 20189:12 amRNSHolding(s) in Company
12th Jul 201811:47 amRNSDirector/PDMR Shareholding
9th Jul 20187:00 amRNSNotice of Results
12th Jun 20184:45 pmRNSDirector/PDMR Shareholding
4th Jun 20185:50 pmRNSDirector/PDMR Shareholding
4th Jun 20189:30 amRNSDirector Declaration
1st Jun 20184:39 pmRNSTotal Voting Rights
1st Jun 20184:37 pmRNSHolding(s) in Company
31st May 201811:57 amRNSDirector/PDMR Shareholding
29th May 20185:34 pmRNSDirector/PDMR Shareholding
22nd May 201812:28 pmRNSHolding(s) in Company
21st May 20184:04 pmRNSHolding(s) in Company
21st May 20187:00 amRNSDirector/PDMR Shareholding
17th May 20184:08 pmRNSHolding(s) in Company
16th May 20181:35 pmRNSResult of AGM
16th May 20187:00 amRNSCompletion of placing
15th May 20184:39 pmRNSProposed placing of shares in Zotefoams plc
14th May 20183:09 pmRNSDirector/PDMR Shareholding
13th Apr 20189:43 amRNSDirector/PDMR Shareholding
12th Apr 20182:27 pmRNS2017 Annual Report and Notice of the 2018 AGM
13th Mar 20185:30 pmRNSDirector/PDMR Shareholding
13th Mar 20187:00 amRNSFinal Results
9th Mar 20187:00 amRNSHolding(s) in Company
22nd Feb 20184:54 pmRNSHolding(s) in Company
22nd Feb 20184:48 pmRNSHolding(s) in Company
13th Feb 20187:00 amRNSDirector/PDMR Shareholding
16th Jan 20184:55 pmRNSHolding(s) in Company
12th Jan 201811:37 amRNSDirector/PDMR Shareholding
22nd Dec 201712:27 pmRNSDirector/PDMR Shareholding
21st Dec 20177:00 amRNSDirectorate Change
18th Dec 20174:10 pmRNSHolding(s) in Company
14th Dec 20177:00 amRNS£12 million investment planned at Croydon facility
13th Dec 20177:00 amRNSDirector/PDMR Shareholding
13th Dec 20177:00 amRNSStrategic Partnership with Nike
15th Nov 20177:00 amRNSDirector/PDMR Shareholding
1st Nov 20177:00 amRNSThird Quarter Trading Update
17th Oct 20171:08 pmRNSDirector/PDMR Shareholding
10th Oct 20177:00 amRNSDirector/PDMR Shareholding
28th Sep 20177:00 amRNSHolding(s) in Company
13th Sep 20177:00 amRNSDirector/PDMR Shareholding
16th Aug 20177:00 amRNSHolding(s) in Company
11th Aug 20175:23 pmRNSHolding(s) in Company
10th Aug 20177:00 amRNSDirector/PDMR Shareholding
8th Aug 20177:00 amRNSDirectorate Changes
8th Aug 20177:00 amRNSHalf-year Report
20th Jul 20177:00 amRNSHolding(s) in Company
12th Jul 201710:19 amRNSDirector/PDMR Shareholding
3rd Jul 20174:35 pmRNSPrice Monitoring Extension
13th Jun 20177:00 amRNSDirector/PDMR Shareholding
5th Jun 20172:14 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.